Login to Your Account



Pharma: Other News To Note


Wednesday, October 17, 2012
• Novo Nordisk A/S, of Bagsvaerd, Denmark, said it submitted a marketing application in Europe and the U.S. for turoctocog alfa, a third-generation recombinant coagulation Factor VIII intended for prevention and treatment of bleeding with people with hemophilia A.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription